Table 1. Selected non-randomized studies reporting outcome of patients with peritoneal carcinomatosis due to metastatic gastric cancer.
| Authors (trial design) | Publication year | Total/HIPEC/other | Agent (dose) | Toxicity | Median follow-up | Clinical outcome |
|---|---|---|---|---|---|---|
| Hultman et al. (24) (Ph II) | 2013 | 18 | CRS/HIPEC/EPIC (5 patients CDDP at 50 mg/m2, 3 patients oxaliplatin 460 mg/m2 with IV 5-FU and LV) | 62.5% grade II-IV adverse event | 14.3 months | 8 patients received entire treatment. OS =14.3 months (95% CI, 6.6-20.3) |
| Wu et al. (25) (RS: ovarian metastasis and peritoneal dissemination) | 2013 | 64, 32 | Oxaliplatin 460 mg/m2 | No difference in grade III/IV AE in HIPEC and non-HIPEC group | 11 months | MS CRS + HIPEC vs. CRS only 15.5 and 10.4 months, P=0.018 |
| Glehen et al. (26) (RS, multicenter) | 2010 | 159 (77 CRS + HIPEC closed, 67 CRS + HIPEC open, 12 CRS + HIPEC + EPIC closed) | (I) MMC 30-150 mg/m2 + CDDP 50-100 mg/m2; (II) OHP 360-460 mg/m2 ± irinotecan 100-200 mg/m2 ± IV 5-FU and leucovorin | Post-op mortality 6.5%; grade 3-4 morbidity 27.8% | 20.4 months | MS 9.2 months; overall 1-, 3-, 5-year survival of 43%, 18%, 13% |
| Hall et al. (27) (RS) | 2004 | 60, 34 | HIPEC with MMC (10 μg/mL, ~40 mg) | 35% HIPEC morbidity vs. 17.5% control | ND | NS, HIPEC 8.0 vs. 7.8 months (P=0.29) |
| Yonemura et al. (28) (RS) | 2005 | 107 | MMC, cisplatin, etoposide at 30, 300, and 150 mg | Not discussed | 46 months | MS 11.5 months, 5-year survival 6.7% |
| Scaringi et al. (29) (RS) | 2008 | 37 (26 with PC, 11 prophylactic) | MMC 120 mg, cisplatin 200 mg/m2 | 10 patients had complications, pulmonary most frequent | ND | MS 23.4 and 6.6 months in prophylactic and PC group, P<0.05 |
| Yonemura et al. (30) (CS) | 1996 | 83 | MMC 30 mg, etoposide 150 mg, cisplatin 300 mg | 3.6% bowel perforation, 2.4% bone marrow suppression, 1.2% renal dysfunction | 46 months | 1- and 5-year survival rates of 43% and 11% |
| Yonemura et al. (31) (CS) | 1991 | 41 | MMC 50 mg, cisplatin 300 mg | Renal insufficiency 5%, leukopenia 5%, bowel perforation 2% | 41.6 months | MS 14.6 months, 3-year survival rate was 28.5% |
Abbreviations: HIPEC, hyperthermic intraperitoneal chemotherapy; CRS, cytoreductive surgery; EPIC, early post-operative intraperitoneal chemotherapy; CDDP, cisplatin; LV, leucovorin; OS, overall survival; RS, retrospective series; MS, median survival; MMC, mitomycin; MS, median survival; ND, not discussed; NS, not significant; PC, peritoneal carcinamotosis; CS, case series.